nach oben

Journal of Neuro-Oncology

Erschienen in:

18.05.2020 | Topic Review

Management of olfactory neuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma involving the skullbase

verfasst von: Gautam U. Mehta, Shaan M. Raza, Shirley Y. Su, Ehab Y. Hanna, Franco DeMonte

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Sinonasal tumors that harbor neuroendocrine histologic features include olfactory neuroblastoma (previously known as esthesioneuroblastoma), sinonasal neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma. These tumors represent a diverse spectrum of clinical behavior and as such require histology-specific management. Herein, we review the management of these sinonasal tumors with neuroendocrine features and discuss fundamentals of multi-modality care for each histology. An emphasis is placed on olfactory neuroblastomas, given their relative frequency and skullbase origin.

Methods

A comprehensive literature review on contemporary management of olfactory neuroblastoma, sinonasal neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma was performed.

Results

Management of sinonasal tumors with neuroendocrine features can include surgical resection, radiation therapy, and/or chemotherapy. Due to their site of origin, these tumors can frequently involve the skullbase, which can require site-specific care. The optimal treatment modalities and the sequence in which they are performed are largely dependent on histology. In most cases, olfactory neuroblastoma is best managed with surgical resection followed by radiation therapy. Sinonasal neuroendocrine carcinomas represent a variety of histologic phenotypes (carcinoid, atypical carcinoid, small cell, and large cell), which determine the optimal treatment modality. Finally, sinonasal undifferentiated carcinoma is likely best managed by induction chemotherapy with subsequent therapy dictated by the initial response.

Conclusions

A team approach to multi-modality care is essential in the treatment of olfactory neuroblastoma, sinonasal neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma. Early biopsy, histologic diagnosis, and comprehensive imaging are critical to determining the appropriate management paradigm.

Dutta R, Dubal PM, Svider PF et al (2015) Sinonasal malignancies: a population-based analysis of site-specific incidence and survival. Laryngoscope 125:2491–2497. https://doi.org/10.1002/lary.25465CrossRefPubMed

Bell D, Hanna EY, Weber RS et al (2016) Neuroendocrine neoplasms of the sinonasal region. Head Neck 38(Suppl 1):E2259–E2266. https://doi.org/10.1002/hed.24152CrossRefPubMed

Su SY, Bell D, Ferrarotto R et al (2017) Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck 39:1671–1679. https://doi.org/10.1002/hed.24822CrossRefPubMed

Elkhatib AH, Soldatova L, Carrau RL et al (2017) Role of 18F-FDG PET/CT differentiating olfactory neuroblastoma from sinonasal undifferentiated carcinoma. Laryngoscope 127:321–324. https://doi.org/10.1002/lary.26194CrossRefPubMed

Cohen ZR, Marmor E, Fuller GN, DeMonte F (2002) Misdiagnosis of olfactory neuroblastoma. Neurosurg Focus 12:e3. https://doi.org/10.3171/foc.2002.12.5.4CrossRefPubMed

Czapiewski P, Kunc M, Haybaeck J (2016) Genetic and molecular alterations in olfactory neuroblastoma—implications for pathogenesis, prognosis and treatment. Oncotarget 7:52584–52596. https://doi.org/10.18632/oncotarget.9683CrossRefPubMedPubMedCentral

Capper D, Engel NW, Stichel D et al (2018) DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathol 136:255–271. https://doi.org/10.1007/s00401-018-1854-7CrossRefPubMed

Hyams VJ (1982) Olfactory neuroblastoma (Case 6). In: Batsakis J, Hyams V, Morales A (eds) Special tumors of the head and neck. ASCP Press, Chicago, pp 24–29

Van Gompel JJ, Giannini C, Olsen KD et al (2012) Long-term outcome of esthesioneuroblastoma: Hyams grade predicts patient survival. J Neurol Surgery B 73:331–336. https://doi.org/10.1055/s-0032-1321512CrossRef

10.

Bell D, Saade R, Roberts D et al (2015) Prognostic utility of Hyams histological grading and Kadish-Morita staging systems for esthesioneuroblastoma outcomes. Head Neck Pathol 9:51–59. https://doi.org/10.1007/s12105-014-0547-3CrossRefPubMed

11.

Kadish S, Goodman M, Wang CC (1976) Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 37:1571–1576. https://doi.org/10.1002/1097-0142(197603)37:3%3c1571:aid-cncr2820370347%3e3.0.co;2-lCrossRefPubMed

12.

Morita A, Ebersold MJ, Olsen KD et al (1993) Esthesioneuroblastoma: prognosis and management. Neurosurgery 32:706–714. https://doi.org/10.1227/00006123-199305000-00002 (discussion 714–715)CrossRefPubMed

13.

Deschler DG, Day T (2008) Pocket guide to tnm staging of head and neck cancer and neck dissection calssification, 3rd edn. American Academy of Otolaryngology-Head and Neck Surgery Foundation, Alexandria

14.

Dulguerov P, Allal AS, Calcaterra TC (2001) Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2:683–690. https://doi.org/10.1016/S1470-2045(01)00558-7CrossRefPubMed

15.

Ketcham AS, Wilkins RH, Van Buren JM, Smith RR (1963) A combined intracranial facial approach to the paranasal sinuses. Am J Surg 106:698–703. https://doi.org/10.1016/0002-9610(63)90387-8CrossRefPubMed

16.

Patel SG, Singh B, Stambuk HE et al (2012) Craniofacial surgery for esthesioneuroblastoma: report of an international collaborative study. J Neurol Surg B 73:208–220. https://doi.org/10.1055/s-0032-1311754CrossRef

17.

Mehta GU, Hanna EY, DeMonte F, Raza SM (2018) Endoscopic endonasal resection of sinonasal/anterior skull base malignancy (Kadish C esthesioneuroblastoma). Acta Neurochir (Wien) 160:361–366. https://doi.org/10.1007/s00701-017-3437-0CrossRef

18.

Hanna E, DeMonte F, Ibrahim S et al (2009) Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol-Head Neck Surg 135:1219–1224. https://doi.org/10.1001/archoto.2009.173CrossRefPubMed

19.

Feiz-Erfan I, Suki D, Hanna E, DeMonte F (2007) Prognostic significance of transdural invasion of cranial base malignancies in patients undergoing craniofacial resection. Neurosurgery 61:1178–1185. https://doi.org/10.1227/01.neu.0000306095.53388.f1 (discussion 1185)CrossRefPubMed

20.

Mays AC, Bell D, Ferrarotto R et al (2018) Early stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb. Laryngoscope 128:1274–1280. https://doi.org/10.1002/lary.26908CrossRefPubMed

21.

Ow TJ, Hanna EY, Roberts DB et al (2014) Optimization of long-term outcomes for patients with esthesioneuroblastoma. Head Neck 36:524–530. https://doi.org/10.1002/hed.23327CrossRefPubMed

22.

Jiang W, Mohamed ASR, Fuller CD et al (2017) The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Pract Radiat Oncol 6:241–247. https://doi.org/10.1016/j.prro.2015.10.023CrossRef

23.

Polin RS, Sheehan JP, Chenelle AG et al (1998) The role of preoperative adjuvant treatment in the management of esthesioneuroblastoma: The University of Virginia experience. Neurosurgery 42:1029–1037. https://doi.org/10.1097/00006123-199805000-00045CrossRefPubMed

24.

Venkatramani R, Pan H, Furman WL et al (2016) Multimodality treatment of pediatric esthesioneuroblastoma. Pediatr Blood Cancer 63:465–470. https://doi.org/10.1002/pbc.25817CrossRefPubMed

25.

Sohrabi S, Drabick JJ, Crist H et al (2011) Neoadjuvant concurrent chemoradiation for advanced esthesioneuroblastoma: a case series and review of the literature. J Clin Oncol 29:e358–e361. https://doi.org/10.1200/JCO.2010.30.9278CrossRefPubMed

26.

Kim DW, Jo YH, Jee HK et al (2004) Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. Cancer 101:2257–2260. https://doi.org/10.1002/cncr.20648CrossRefPubMed

27.

Wang L, Ding Y, Wei L et al (2016) Recurrent olfactory neuroblastoma treated with cetuximab and sunitinib a case report. Medicine (United States) 95:e3536. https://doi.org/10.1097/MD.0000000000003536CrossRef

28.

Preusser M, Hutterer M, Sohm M et al (2010) Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate. J Neurooncol 97:305–308. https://doi.org/10.1007/s11060-009-0027-xCrossRefPubMed

29.

London NR, Rooper LM, Bishop JA et al (2020) Expression of programmed cell death ligand 1 and associated lymphocyte infiltration in olfactory neuroblastoma. World Neurosurg 135:e187–e193. https://doi.org/10.1016/j.wneu.2019.11.112CrossRefPubMed

30.

van der Laan TP, Iepsma R, Witjes MJH et al (2016) Meta-analysis of 701 published cases of sinonasal neuroendocrine carcinoma: the importance of differentiation grade in determining treatment strategy. Oral Oncol 63:1–9. https://doi.org/10.1016/j.oraloncology.2016.10.002CrossRefPubMed

31.

Mitchell EH, Diaz A, Yilmaz T et al (2012) Multimodality treatment for sinonasal neuroendocrine carcinoma. Head Neck 34:1372–1376. https://doi.org/10.1002/hed.21940CrossRefPubMed

32.

Turri-Zanoni M, Maragliano R, Battaglia P et al (2017) The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: refinements in diagnostic criteria and impact of multimodal treatments on survival. Oral Oncol 74:21–29. https://doi.org/10.1016/j.oraloncology.2017.09.010CrossRefPubMed

33.

Ferlito A, Devaney KO, Rinaldo A (2006) Neuroendocrine neoplasms of the larynx: advances in identification, understanding, and management. Oral Oncol 42:770–788. https://doi.org/10.1016/j.oraloncology.2006.01.002CrossRefPubMed

34.

Likhacheva A, Rosenthal D, Hanna E et al (2011) Sinonasal neuroendocrine carcinoma: impact of differentiation status on response and outcome. Head Neck Oncol 3:1–6. https://doi.org/10.1186/1758-3284-3-32CrossRef

35.

Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227–232. https://doi.org/10.1002/1097-0142(19910715)68:2%3c227:aid-cncr2820680202%3e3.0.co;2-iCrossRefPubMed

36.

Fitzek MM, Thornton AF, Varvares M et al (2002) Neuroendocrine tumors of the sinonasal tract: results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer 94:2623–2634. https://doi.org/10.1002/cncr.10537CrossRefPubMed

37.

Fried D, Zanation AM, Huang B et al (2012) Management of nonesthesioneuroblastoma sinonasal malignancies with neuroendocrine differentiation. Laryngoscope 122:2210–2215. https://doi.org/10.1002/lary.23463CrossRefPubMed

38.

Tanzler ED, Morris CG, Orlando CA et al (2008) Management of sinonasal undifferentiated carcinoma. Head Neck 30:595–599. https://doi.org/10.1002/hed.20748CrossRefPubMed

39.

Mendenhall WM, Mendenhall CM, Riggs CE et al (2006) Sinonasal undifferentiated carcinoma. Am J Clin Oncol Cancer Clin Trials 29:27–31. https://doi.org/10.1097/01.coc.0000189691.04140.02CrossRef

40.

Musy PY, Reibel JF, Levine PA (2002) Sinonasal undifferentiated carcinoma; the search for a better outcome. Laryngoscope 112:1450–1455. https://doi.org/10.1097/00005537-200208000-00023CrossRefPubMed

41.

Rischin D, Porceddu S, Peters L et al (2004) Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. Head Neck 26:435–441. https://doi.org/10.1002/hed.10396CrossRefPubMed

42.

Amit M, Abdelmeguid AS, Watcherporn T et al (2019) Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol 37:504–512. https://doi.org/10.1200/JCO.18.00353CrossRefPubMedPubMedCentral

43.

Al-Mamgani A, van Rooij P, Mehilal R et al (2013) Combined-modality treatment improved outcome in sinonasal undifferentiated carcinoma: single-institutional experience of 21 patients and review of the literature. Eur Arch Otorhinolaryngol 270:293–299. https://doi.org/10.1007/s00405-012-2008-5CrossRefPubMed

44.

Gamez ME, Lal D, Halyard MY et al (2017) Outcomes and patterns of failure for sinonasal undifferentiated carcinoma (SNUC): the mayo clinic experience. Head Neck 39:1819–1824. https://doi.org/10.1002/hed.24834CrossRefPubMed

45.

Kim BS, Vongtama R, Juillard G (2004) Sinonasal undifferentiated carcinoma: case series and literature review. Am J Otolaryngol-Head Neck Med Surg 25:162–166. https://doi.org/10.1016/j.amjoto.2003.12.002CrossRef

46.

Revenaugh PC, Seth R, Pavlovich JB et al (2011) Minimally invasive endoscopic resection of sinonasal undifferentiated carcinoma. Am J Otolaryngol-Head Neck Med Surg 32:464–469. https://doi.org/10.1016/j.amjoto.2010.09.006CrossRef

47.

Chen AM, Daly ME, El-Sayed I et al (2008) Patterns of failure after combined-modality approaches incorporating radiotherapy for sinonasal undifferentiated carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 70:338–343. https://doi.org/10.1016/j.ijrobp.2007.06.057CrossRefPubMed

Titel: Management of olfactory neuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma involving the skullbase
verfasst von: Gautam U. Mehta
Shaan M. Raza
Shirley Y. Su
Ehab Y. Hanna
Franco DeMonte
Publikationsdatum: 18.05.2020
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03537-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Ophthalmic and orbital considerations in the evaluation of skull base malignancies

Surgical management of anterior skull-base malignancies (endoscopic vs. craniofacial resection)

Radiation therapy strategies for skull-base malignancies

Temporal bone resection for lateral skull-base malignancies

Management considerations for malignant tumors of the skull base